Skip to main content
. 2014 Oct 29;10:2039–2047. doi: 10.2147/NDT.S68273

Figure 1.

Figure 1

Change in ADHD-RS-IV total scores from baseline to endpoint in treatment-naïve and previously treated patients (full analysis set).

Notes: ADHD-RS-IV total scores are shown as mean values ±95% CIs. In the left hand panel, open symbols indicate mean baseline scores and closed symbols indicate mean endpoint scores (LDX, circles; placebo, triangles; OROS-MPH, squares). The difference (active drug minus placebo) in LS mean change (±95% CI) from baseline to endpoint is also shown (LDX, circles; OROS-MPH, squares). Gray shading on the left hand panel indicates the 95% CI for the mean ADHD-RS-IV total score at endpoint in the LDX group in the overall study population. On the right hand panel, gray shading indicates the 95% CI for the difference (LDX minus placebo) in LS mean change from baseline to endpoint in the overall study population. Endpoint is the last on-therapy assessment visit with a valid ADHD-RS-IV total score. Immediately prior to randomization is defined as up to 30 days prior to randomization.

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; ADHD-RS-IV, ADHD rating scale IV; CI, confidence interval; LDX, lisdexamfetamine dimesylate; LS, least-squares; MPH, methylphenidate; OROS-MPH, osmotic-release oral system MPH.